Bedrijfsoverzicht
Anbio Biotechnology is a provider of in vitro diagnostics (IVD) solutions that serves a global footprint spanning the European Union, Asia Pacific, North America, South America, Africa, and international markets. The company specializes in offering SARS-CoV-2 antigen rapid tests, SARS-CoV-2/influenza A/B antigen rapid tests, as well as lateral flow immunoassays and fluorescence immunoassays within the healthcare sector. It operates specifically within the Medical Instruments & Supplies industry, a segment characterized by the development, manufacturing, and distribution of essential medical equipment and diagnostic tools. The company currently possesses a market capitalization of $1.19B, while its trailing twelve-month revenue stands at $8.65M. The absence of disclosed employee count data limits a direct assessment of workforce scale, yet the valuation metrics suggest the market assigns a significant premium to its product portfolio and technological capabilities.
Financiële gezondheid
The company reported annual revenue of $8.65M over the trailing twelve months, generating a net income of $6.40M, while EBITDA figures are not disclosed in the available data. The substantial difference between the $8.65M revenue and the $6.40M net income indicates a highly efficient cost structure where operating expenses and taxes consume only a fraction of total sales. However, the free cash flow stands at -$9,605,703, which signifies that despite accounting profits, the company is currently burning cash, potentially due to heavy capital expenditures or working capital requirements for its diagnostic operations. Despite this negative cash flow, the balance sheet remains robust with $11.90M in cash and zero recorded debt. The gross margin is reported at 87.2%, reflecting the high value added by the company's proprietary diagnostic tests relative to their production costs. Furthermore, the operating margin reaches 59.1%, and the profit margin is an impressive 74.1%, demonstrating exceptional control over costs and high profitability on every dollar of revenue. With zero debt, the debt-to-equity ratio is effectively nil, confirming a conservative and non-leveraged balance sheet structure. Liquidity is exceptionally strong, evidenced by a current ratio of 344.31, which indicates an overwhelming ability to meet short-term obligations with current assets. Management effectiveness is highlighted by a return on equity of 27.0% and a return on assets of 14.7%, metrics that reveal the company generates substantial returns relative to the capital invested by shareholders and the total asset base.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is 180.67, whereas the forward P/E is not available, implying that analysts or the market may have significant uncertainty regarding the future earnings trajectory or that forward earnings estimates have not yet been established. The price-to-book ratio is 43.15, which indicates a substantial market premium where the stock price is valued at over 43 times the company's book value. This high multiple suggests that the market prices the company based on its intangible assets, intellectual property, and growth potential rather than its tangible book value. The price-to-sales ratio is 137.56, and the EV/EBITDA is not available, suggesting that valuation is primarily driven by revenue generation capabilities rather than earnings multiples. The 52-week high is $55.65 and the 52-week low is $6.02, illustrating an extreme price volatility and a wide trading range over the past year. Without the current price explicitly provided in the facts, the specific percentage deviation from the high or low cannot be calculated, but the range itself highlights the speculative nature of the security. The beta value is not available, so a direct comparison of price volatility relative to the broader market index cannot be made using the provided data points.
Growth & Income
Revenue growth year-over-year is 73.9%, while earnings growth year-over-year is not available to calculate a direct comparison between the two rates. The absence of earnings growth data prevents a definitive statement on whether profitability is expanding faster or slower than the top line, though the high profit margins suggest efficiency is being maintained. The company does not pay a dividend, as indicated by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company reinvests all of its generated net income back into the business, likely funding research and development or capacity expansion to support its global IVD operations. Since the firm does not distribute cash to shareholders, the growth profile is entirely dependent on operational expansion and potential future acquisitions rather than income distribution. The overall profile presents a high-growth, non-dividend equity with a capital-light cost structure that prioritizes internal reinvestment over shareholder payouts.